Skip to main content
Fig. 1 | The Journal of Headache and Pain

Fig. 1

From: Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study

Fig. 1

Patient Flowchart and Disposition. All patients were started on 140-mg erenumab and received this dose from week 1 through week 12. After the initial 12 weeks of treatment, all patients had a dose reduction and received 70 mg erenumab from week 13 through week 24. From week 24 through week 52, patients continued with the dose with the highest efficacy (140-mg or 70-mg). Final evaluation was conducted at week 52

Back to article page